Business Context and Reporting Period
This Form 8-K was filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on January 5, 2023. The report discloses a specific corporate event regarding intellectual property rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a non-financial event and does not contain financial statements.
Material Changes
The material change reported is the issuance of a new patent by the U.S. Patent and Trademark Office on December 27, 2022:
- Patent Number: U.S. Patent No. 11,535,603
- Title: "Deuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides and Methods of Treating Medical Disorders Using Same"
- Scope: Covers the composition of matter for novel molecular glue degraders, including the Company's preclinical cereblon-binding compound, SP-3204.
- Expiration: The patent is valid through September 2037.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond the general context of patent protection. The primary implication is the strengthening of the Company's intellectual property portfolio for its preclinical pipeline.
Investor Verification Checklist
- Verify the status of the preclinical compound SP-3204 and its development timeline.
- Confirm the specific claims within U.S. Patent No. 11,535,603 to understand the breadth of protection.
- Review the press release filed as Exhibit 99.1 for additional details on the patent's strategic value.
- Note that this filing does not contain financial data; refer to the most recent 10-K or 10-Q for financial health metrics.